Literature DB >> 2935482

Cutaneous adverse reactions to acyclovir: case reports.

G E Robinson, J Weber, C Griffiths, G S Underhill, D J Jeffries, D Goldmeir.   

Abstract

Intravenous, oral, and topical formulations of acyclovir have been successful in treating genital herpes. We report on two patients who developed skin reactions while taking acyclovir, which resolved when treatment was stopped.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2935482      PMCID： PMC1011759          DOI： 10.1136/sti.61.1.62

Source DB:  PubMed          Journal:  Genitourin Med        ISSN： 0266-4348


  5 in total

1.  Intravenous acyclovir treatment for primary genital herpes.

Authors:  A Mindel; M W Adler; S Sutherland; A P Fiddian
Journal:  Lancet       Date:  1982-03-27       Impact factor: 79.321

2.  Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes.

Authors:  A E Nilsen; T Aasen; A M Halsos; B R Kinge; E A Tjøtta; K Wikström; A P Fiddian
Journal:  Lancet       Date:  1982-09-11       Impact factor: 79.321

3.  A trial of topical acyclovir in genital herpes simplex virus infections.

Authors:  L Corey; A J Nahmias; M E Guinan; J K Benedetti; C W Critchlow; K K Holmes
Journal:  N Engl J Med       Date:  1982-06-03       Impact factor: 91.245

4.  Preliminary studies of acyclovir in chronic hepatitis B.

Authors:  C I Smith; G H Scullard; P B Gregory; W S Robinson; T C Merigan
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

5.  Acyclovir halts progression of herpes zoster in immunocompromised patients.

Authors:  H H Balfour; B Bean; O L Laskin; R F Ambinder; J D Meyers; J C Wade; J A Zaia; D Aeppli; L E Kirk; A C Segreti; R E Keeney
Journal:  N Engl J Med       Date:  1983-06-16       Impact factor: 91.245
  5 in total
  5 in total

Review 1.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

2.  Localized bullous eruptions away from infusion site due to intravenous acyclovir administration in a child.

Authors:  Asuman Gurkan; Nilgun Erkek; Saliha Senel
Journal:  Indian J Pharmacol       Date:  2012-01       Impact factor: 1.200

3.  Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity.

Authors:  Imir G Metushi; Amanda Wriston; Priyanka Banerjee; Bjoern Oliver Gohlke; A Michelle English; Andrew Lucas; Carrie Moore; John Sidney; Soren Buus; David A Ostrov; Simon Mallal; Elizabeth Phillips; Jeffrey Shabanowitz; Donald F Hunt; Robert Preissner; Bjoern Peters
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

4.  Delayed allergy to acyclovir revealed by lymphocyte proliferation test.

Authors:  Marcello Albanesi; Attilio Di Girolamo; Vincenzo Aresta; Maria Pia Rossi; Lucia Giliberti; Tommasina Perrone; Danilo Di Bona; Maria Filomena Caiaffa; Giorgina Specchia; Luigi Macchia
Journal:  Postepy Dermatol Alergol       Date:  2018-07-19       Impact factor: 1.837

5.  Adverse drug reactions triggered by the common HLA-B*57:01 variant: virtual screening of DrugBank using 3D molecular docking.

Authors:  George Van Den Driessche; Denis Fourches
Journal:  J Cheminform       Date:  2018-01-30       Impact factor: 5.514
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.